QN
QNTM.US Quantum BioPharma Ltd.
- Market cap
- USD 10.2M
- P/E
- -
- P/B
- 1.73x
- ROE
- -190.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QNTM.US undervalued?
Graham numberThe Graham number of Quantum BioPharma Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Quantum BioPharma Ltd. fundamental analysis
No fundamental analysis for Quantum BioPharma Ltd. yet.
Quantum BioPharma Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a paten…
Full company profileQuantum BioPharma Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Quantum BioPharma Ltd. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 20.6K | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | 20.6K | -183K | -2.65M | - | - | - | - | -491K | -555K | -507K |
| Operating Income | - | -2.80M | - | -30.6M | -30.7M | -33.7M | -27.4M | -23.8M | -16.1M | -15.3M | -11.6M |
| EBITDA | -29.6K | -2.80M | -16.5M | -32.0M | -24.3M | -29.8M | -22.1M | -15.7M | -14.4M | -25.8M | -25.3M |
| Net Income | -29.6K | -2.80M | -22.6M | -39.1M | -31.8M | -35.3M | -23.6M | -17.9M | -14.2M | -26.2M | -22.5M |
| EPS | -0.29 | -28 | -249 | -360 | -172 | -66 | -40 | -29 | -12 | -7.97 | -2.81 |
| Balance Sheet | |||||||||||
| Total Assets | 7.14K | 10.9M | 38.7M | 43.2M | 42.0M | 63.0M | 38.4M | 17.5M | 17.1M | 11.1M | 17.3M |
| Total Liabilities | 61.4K | 1.01M | 1.28M | 6.94M | 5.66M | 8.83M | 7.87M | 4.57M | 6.68M | 6.05M | 7.56M |
| Shareholders' Equity | -54.3K | 9.87M | 37.5M | 36.3M | 36.3M | 54.1M | 30.5M | 13.2M | 11.5M | 6.91M | 11.8M |
| Cash & Short-term Investments | 7.14K | 3.77M | 15.5M | 5.97M | 17.5M | 35.4M | 17.0M | 3.51M | 7.20M | 6.17M | 12.4M |
| Total Debt | - | - | - | 1.59M | 511K | 556K | 516K | 339K | 825K | 1.87M | 924K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.2K | -119K | -13.6M | -13.7M | -19.1M | -20.7M | -28.3M | -10.8M | -6.88M | -8.38M | -8.18M |
| Capital Expenditure | 0.00 | 6.09M | 2.96M | 293K | 3.46 | 500K | 364K | 2.20 | 1.43 | 0.00 | 8.00 |
| Free Cash Flow | -27.2K | -6.21M | -16.5M | -14.0M | -19.1M | -21.2M | -28.7M | -10.8M | -6.88M | -8.38M | -8.18M |
| Ratios | |||||||||||
| ROE | - | -28.4% | -60.4% | -107.9% | -87.6% | -65.2% | -77.3% | -135.2% | -123.7% | -378.7% | -190.2% |
| ROA | -415.1% | -25.8% | -58.4% | -90.5% | -75.8% | -56.0% | -61.5% | -102.4% | -83.0% | -235.0% | -129.6% |
| Net Profit Margin | - | -13,586.0% | - | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.04x | 0.01x | 0.01x | 0.02x | 0.03x | 0.07x | 0.27x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Quantum BioPharma Ltd. dividends
Quantum BioPharma Ltd. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:65 on Aug 15, 2024.
Who owns Quantum BioPharma Ltd.
- Insiders 7.46%
- Institutions 11.63%
- Public & others 80.91%
- Shares outstanding 6.43M
- Free float 7.64M
Top funds holding QNTM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 11.0K | 0.14% | 0.00% | Oct 2026 |
Top institutions holding QNTM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 204K | 2.52% | +87.46% | Jun 2026 |
| Jane Street Group LLC | 48.4K | 0.60% | +53.50% | Jun 2026 |
| Platform Technology Partners | 41.1K | 0.51% | 0.00% | Jun 2026 |
| UBS Group AG | 33.4K | 0.41% | +361.59% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 27.9K | 0.34% | +536.41% | Jun 2026 |
| Citadel Advisors Llc | 15.9K | 0.20% | 0.00% | Jun 2026 |
| Marex Group Ltd | 13.4K | 0.17% | -0.24% | Jun 2026 |
| Mariner Wealth Advisors LLC | 10.0K | 0.12% | -0.59% | Jun 2026 |
| Nbc Securities Inc | 7.00K | 0.09% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 6.30K | 0.08% | -1.25% | Jun 2026 |
| Global Retirement Partners, LLC. | 3.00K | 0.04% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.21K | 0.01% | +72.71% | Jun 2026 |
| Atlantic Union Bankshares Corp | 1.00K | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 600.00 | 0.01% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 446.00 | 0.01% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 250.00 | 0.00% | +150.00% | Jun 2026 |
| Cetera Trust Co NA | 250.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 190.00 | 0.00% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 93.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 79.00 | 0.00% | +5.33% | Jun 2026 |
Quantum BioPharma Ltd. company profile
- Company name
- Quantum BioPharma Ltd.
- Ticker
- QNTM.US
- ISIN
- CA74764Y2050
- Exchange
- USA Stocks
- Listed since
- Jun 8, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1 Adelaide Street East, Toronto, ON, Canada, M5C 2V9
- Phone
- 833-304-0323
- Website
- quantumbiopharma.com
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.
Quantum BioPharma Ltd. management
10- Mr. Zeeshan SaeedCo-Founder, CEO & Executive Non-Independent Co-Chairman · born 1970
- Mr. Anthony John DurkaczCo-Founder & Executive Non-Independent Co-Chairman · born 1976
- Mr. Donal Carroll C.M.A., CPAChief Financial Officer · born 1977
- Dr. Andrzej Chruscinski M.D., Ph.D.President of Clinical & Scientific Affairs
- Mr. Nathan Coyle CPAController · born 1981
- Dr. Ashwini Joshi M.S.Vice-President of Pharmaceutical Development
- Dr. Patrick Onyango Ph.D.Director of Operations at U.S.
- Mr. Jason David SawyerHead of Finance & Mergers and Acquisitions · born 1972
- Ms. Maryann AdessoCorporate Secretary
- Randell MackPresident of FSD BioSciences